1
|
Gasull-Camós J, Soto-Montenegro ML, Casquero-Veiga M, Desco M, Artigas F, Castañé A. Differential Patterns of Subcortical Activity Evoked by Glial GLT-1 Blockade in Prelimbic and Infralimbic Cortex: Relationship to Antidepressant-Like Effects in Rats. Int J Neuropsychopharmacol 2017; 20:988-993. [PMID: 29016806 PMCID: PMC5716080 DOI: 10.1093/ijnp/pyx067] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 07/28/2017] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Glutamatergic neurotransmission has emerged as a novel target in antidepressant drug development, with a critical role of the ventral anterior cingulate cortex. We recently reported that blockade of the astrocytic glutamate transporter GLT-1 with dihydrokainic acid in infralimbic cortex (rodent equivalent of ventral anterior cingulate cortex), but not in the adjacent prelimbic cortex, evoked robust antidepressant-like effects through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation and increased serotonin release. METHODS 2-deoxy-2-[18F]-fluoro-D-glucose-positron emission tomography and computed tomography in 36 male Wistar rats microinfused bilaterally in prelimbic cortex or infralimbic cortex with dihydrokainic acid or vehicle. RESULTS Dihydrokainic acid microinfusion in infralimbic cortex and prelimbic cortex evoked dramatically different regional patterns of subcortical activity. In infralimbic cortex, dihydrokainic acid selectively affected midbrain areas, whereas in prelimbic cortex it affected the basal ganglia, the thalamus, and both superior and inferior colliculi. CONCLUSIONS These results highlight the differential connectivity of infralimbic and prelimbic cortex with subcortical brain regions and support the involvement of infralimbic cortex-midbrain pathway in the antidepressant-like effects of dihydrokainic acid.
Collapse
Affiliation(s)
- Júlia Gasull-Camós
- Department of Neurochemistry and Neuropharmacology, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain (Drs Artigas, Castañé, Desco and Soto-Montenegro, Ms Casquero-Veiga and Ms Gasull-Camós); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Drs Desco and Soto-Montenegro and Ms Casquero-Veiga); Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain (Dr Desco); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Dr Desco)
| | - Maria Luisa Soto-Montenegro
- Department of Neurochemistry and Neuropharmacology, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain (Drs Artigas, Castañé, Desco and Soto-Montenegro, Ms Casquero-Veiga and Ms Gasull-Camós); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Drs Desco and Soto-Montenegro and Ms Casquero-Veiga); Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain (Dr Desco); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Dr Desco)
| | - Marta Casquero-Veiga
- Department of Neurochemistry and Neuropharmacology, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain (Drs Artigas, Castañé, Desco and Soto-Montenegro, Ms Casquero-Veiga and Ms Gasull-Camós); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Drs Desco and Soto-Montenegro and Ms Casquero-Veiga); Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain (Dr Desco); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Dr Desco)
| | - Manuel Desco
- Department of Neurochemistry and Neuropharmacology, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain (Drs Artigas, Castañé, Desco and Soto-Montenegro, Ms Casquero-Veiga and Ms Gasull-Camós); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Drs Desco and Soto-Montenegro and Ms Casquero-Veiga); Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain (Dr Desco); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Dr Desco)
| | - Francesc Artigas
- Department of Neurochemistry and Neuropharmacology, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain (Drs Artigas, Castañé, Desco and Soto-Montenegro, Ms Casquero-Veiga and Ms Gasull-Camós); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Drs Desco and Soto-Montenegro and Ms Casquero-Veiga); Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain (Dr Desco); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Dr Desco)
| | - Anna Castañé
- Department of Neurochemistry and Neuropharmacology, CSIC-Institut d’Investigacions Biomèdiques de Barcelona, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain (Drs Artigas and Castañé and Ms Gasull-Camós); Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain (Drs Artigas, Castañé, Desco and Soto-Montenegro, Ms Casquero-Veiga and Ms Gasull-Camós); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain (Drs Desco and Soto-Montenegro and Ms Casquero-Veiga); Departamento de Bioingeniería e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Spain (Dr Desco); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Dr Desco),Correspondence: Anna Castañé, PhD, Department of Neurochemistry and Neuropharmacology, Rosselló 161 6th Floor, 08036 Barcelona, Spain ()
| |
Collapse
|
2
|
Morioka N, Tokuhara M, Nakamura Y, Idenoshita Y, Harano S, Zhang FF, Hisaoka-Nakashima K, Nakata Y. Primary cultures of rat cortical microglia treated with nicotine increases in the expression of excitatory amino acid transporter 1 (GLAST) via the activation of the α7 nicotinic acetylcholine receptor. Neuroscience 2013; 258:374-84. [PMID: 24300109 DOI: 10.1016/j.neuroscience.2013.11.044] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2013] [Revised: 11/22/2013] [Accepted: 11/23/2013] [Indexed: 10/25/2022]
Abstract
Although the clearance of glutamate from the synapse under physiological conditions is performed by astrocytic glutamate transporters, their expression might be diminished under pathological conditions. Microglia glutamate transporters, however, might serve as a back-up system when astrocytic glutamate uptake is impaired, and could have a prominent neuroprotective function under pathological conditions. In the current study, the effect of nicotine, well known as a neuroprotective molecule, on the function of glutamate transporters in cultured rat cortical microglia was examined. Reverse transcription polymerase chain reaction and pharmacological approaches demonstrated that, glutamate/aspartate transporter (GLAST), not glutamate transporter 1 (GLT-1), is the major functional glutamate transporter in cultured cortical microglia. Furthermore, the α7 subunit was demonstrated to be the key subunit comprising nicotinic acetylcholine (nACh) receptors in these cells. Treatment of cortical microglia with nicotine led to a significant increase of GLAST mRNA expression and (14)C-glutamate uptake in a concentration- and time-dependent manner, which were markedly inhibited by pretreatment with methyllycaconitine, a selective α7 nACh receptor antagonist. The nicotine-induced expression of GLAST mRNA and protein is mediated through an inositol trisphosphate (IP3) and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) depend intracellular pathway, since pretreatment with either xestospongin C, an IP3 receptor antagonist, or KN-93, a CaMKII inhibitor, blocked GLAST expression. Together, these findings indicate that activation of nACh receptors, specifically those expressing the α7 subunit, on cortical microglia could be a key mechanism of the neuroprotective effect of nACh receptor ligands such as nicotine.
Collapse
Affiliation(s)
- N Morioka
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
| | - M Tokuhara
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Y Nakamura
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Y Idenoshita
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - S Harano
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - F F Zhang
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - K Hisaoka-Nakashima
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Y Nakata
- Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| |
Collapse
|
3
|
John CS, Smith KL, Van'T Veer A, Gompf HS, Carlezon WA, Cohen BM, Öngür D, Bechtholt-Gompf AJ. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology 2012; 37:2467-75. [PMID: 22739467 PMCID: PMC3442341 DOI: 10.1038/npp.2012.105] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Major depression is associated with both dysregulated glutamatergic neurotransmission and fewer astrocytes in limbic areas including the prefrontal cortex (PFC). These deficits may be functionally related. Notably, astrocytes regulate glutamate levels by removing glutamate from the synapse via the glutamate transporter (GLT-1). Previously, we demonstrated that central blockade of GLT-1 induces anhedonia and c-Fos expression in the PFC. Given the role of the PFC in regulating mood, we hypothesized that GLT-1 blockade in the PFC alone would be sufficient to induce anhedonia in rats. We microinjected the GLT-1 inhibitor, dihydrokainic acid (DHK), into the PFC and examined the effects on mood using intracranial self-stimulation (ICSS). At lower doses, intra-PFC DHK produced modest increases in ICSS thresholds, reflecting a depressive-like effect. At higher doses, intra-PFC DHK resulted in cessation of responding. We conducted further tests to clarify whether this total cessation of responding was related to an anhedonic state (tested by sucrose intake), a nonspecific result of motor impairment (measured by the tape test), or seizure activity (measured with electroencephalogram (EEG)). The highest dose of DHK increased latency to begin drinking without altering total sucrose intake. Furthermore, neither motor impairment nor evidence of seizure activity was observed in the tape test or EEG recordings. A decrease in reward value followed by complete cessation of ICSS responding suggests an anhedonic-like effect of intra-PFC DHK; a conclusion that was substantiated by an increased latency to begin sucrose drinking. Overall, these results suggest that blockade of astrocytic glutamate uptake in the PFC is sufficient to produce anhedonia, a core symptom of depression.
Collapse
Affiliation(s)
- Catherine S John
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - Karen L Smith
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - Ashlee Van'T Veer
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - Heinrich S Gompf
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - William A Carlezon
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - Bruce M Cohen
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - Dost Öngür
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA
| | - Anita J Bechtholt-Gompf
- Department of Psychiatry, Harvard Medical School–McLean Hospital, Belmont, MA, USA,Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill Street, MRC 215, Belmont, MA 02478, USA, Tel: +1 617 855 2050, Fax: +1 617 855 2023, E-mail:
| |
Collapse
|
4
|
Bechtholt-Gompf AJ, Walther HV, Adams MA, Carlezon WA, Öngür D, Cohen BM. Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology 2010; 35:2049-59. [PMID: 20531459 PMCID: PMC3055299 DOI: 10.1038/npp.2010.74] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Mood disorders are associated with regional brain abnormalities, including reductions in glial cell and neuron number, glutamatergic irregularities, and differential patterns of brain activation. Because astrocytes are modulators of neuronal activity and are important in trafficking the excitatory neurotransmitter glutamate, it is possible that these pathologies are interrelated and contribute to some of the behavioral signs that characterize depression and related disorders. We tested this hypothesis by determining whether depressive-like signs were induced by blocking central astrocytic glutamate uptake with the astrocytic glutamate transporter (GLT-1) inhibitor, dihydrokainic acid (DHK), in behavioral tests that quantify aspects of mood, including reward and euthymia/dysthymia: intracranial self-stimulation (ICSS) and place conditioning. We found that DHK elevated ICSS thresholds, a depressive-like effect that could reflect reduced sensitivity to reward (anhedonia) or increased aversion (dysphoria). However, DHK treatment did not establish conditioned place aversions, suggesting that this treatment does not induce dysphoria. To identify the brain regions mediating the behavioral effects of DHK, we examined c-Fos expression in areas implicated in motivation and emotion. DHK increased c-Fos expression in many of these regions. The dentate gyrus of the hippocampus was robustly activated, which led us to explore whether DHK alters hippocampal learning. DHK impaired spatial memory in the MWM. These findings identify disruption of astrocyte glutamate uptake as one component of the complex circuits that mediate anhedonia and cognitive impairment, both of which are common symptoms of depression. These finding may have implications for the etiology of depression and other disorders that share the features of anhedonia and cognitive impairment.
Collapse
Affiliation(s)
| | - Hali V Walther
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| | - Martha A Adams
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| | - William A Carlezon
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| | - Dost Öngür
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| | - Bruce M Cohen
- Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, USA
| |
Collapse
|